Ticagrelor monotherapy in CKD: better safety at what price?

Saved in:
Bibliographic Details
Published in:European heart journal 2021-12, Vol.42 (45), p.4694-4696
Main Authors: Parker, William A E, Storey, Robert F
Format: Article
Language:English
Subjects:
Humans
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors - adverse effects
Renal Insufficiency, Chronic - drug therapy
Ticagrelor - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c301t-e56697432d8c5f43a61cf7f23a63de3d11d51fc030f0fab331e5f4cb02cbf3143
cites cdi_FETCH-LOGICAL-c301t-e56697432d8c5f43a61cf7f23a63de3d11d51fc030f0fab331e5f4cb02cbf3143
container_end_page 4696
container_issue 45
container_start_page 4694
container_title European heart journal
container_volume 42
creator Parker, William A E
Storey, Robert F
description
doi_str_mv 10.1093/eurheartj/ehab607
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2569374454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2569374454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-e56697432d8c5f43a61cf7f23a63de3d11d51fc030f0fab331e5f4cb02cbf3143</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqXwAWxQlmxCx_EjCSwQKk9RiU2R2FmOMyapkqbYjlD_nlQt3czM4tyr0SHkksINhZxNsXcVaheWU6x0ISE9ImMqkiTOJRfHZAw0F7GU2deInHm_BIBMUnlKRozzDASHMblb1EZ_O2w6F7XdqgsVOr3eRPUqmr0_3kYFhoAu8tpi2EQ6RL_VMNauNnh_Tk6sbjxe7PeEfD4_LWav8fzj5W32MI8NAxpiFFLmKWdJmRlhOdOSGpvaZDhYiayktBTUGmBgweqCMYoDZgpITGEZ5WxCrne9a9f99OiDamtvsGn0Crveq0TInKWciy1Kd6hxnfcOrRpebbXbKApq60wdnKm9syFzta_vixbLQ-JfEvsDcqVq4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2569374454</pqid></control><display><type>article</type><title>Ticagrelor monotherapy in CKD: better safety at what price?</title><source>Oxford Journals Online</source><creator>Parker, William A E ; Storey, Robert F</creator><creatorcontrib>Parker, William A E ; Storey, Robert F</creatorcontrib><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehab607</identifier><identifier>PMID: 34480540</identifier><language>eng</language><publisher>England</publisher><subject>Humans ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors - adverse effects ; Renal Insufficiency, Chronic - drug therapy ; Ticagrelor - adverse effects</subject><ispartof>European heart journal, 2021-12, Vol.42 (45), p.4694-4696</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c301t-e56697432d8c5f43a61cf7f23a63de3d11d51fc030f0fab331e5f4cb02cbf3143</citedby><cites>FETCH-LOGICAL-c301t-e56697432d8c5f43a61cf7f23a63de3d11d51fc030f0fab331e5f4cb02cbf3143</cites><orcidid>0000-0002-6677-6229 ; 0000-0002-7822-8852</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34480540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parker, William A E</creatorcontrib><creatorcontrib>Storey, Robert F</creatorcontrib><title>Ticagrelor monotherapy in CKD: better safety at what price?</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><subject>Humans</subject><subject>Percutaneous Coronary Intervention</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Ticagrelor - adverse effects</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EoqXwAWxQlmxCx_EjCSwQKk9RiU2R2FmOMyapkqbYjlD_nlQt3czM4tyr0SHkksINhZxNsXcVaheWU6x0ISE9ImMqkiTOJRfHZAw0F7GU2deInHm_BIBMUnlKRozzDASHMblb1EZ_O2w6F7XdqgsVOr3eRPUqmr0_3kYFhoAu8tpi2EQ6RL_VMNauNnh_Tk6sbjxe7PeEfD4_LWav8fzj5W32MI8NAxpiFFLmKWdJmRlhOdOSGpvaZDhYiayktBTUGmBgweqCMYoDZgpITGEZ5WxCrne9a9f99OiDamtvsGn0Crveq0TInKWciy1Kd6hxnfcOrRpebbXbKApq60wdnKm9syFzta_vixbLQ-JfEvsDcqVq4A</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Parker, William A E</creator><creator>Storey, Robert F</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6677-6229</orcidid><orcidid>https://orcid.org/0000-0002-7822-8852</orcidid></search><sort><creationdate>20211201</creationdate><title>Ticagrelor monotherapy in CKD: better safety at what price?</title><author>Parker, William A E ; Storey, Robert F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-e56697432d8c5f43a61cf7f23a63de3d11d51fc030f0fab331e5f4cb02cbf3143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Humans</topic><topic>Percutaneous Coronary Intervention</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Ticagrelor - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parker, William A E</creatorcontrib><creatorcontrib>Storey, Robert F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parker, William A E</au><au>Storey, Robert F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ticagrelor monotherapy in CKD: better safety at what price?</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>42</volume><issue>45</issue><spage>4694</spage><epage>4696</epage><pages>4694-4696</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><cop>England</cop><pmid>34480540</pmid><doi>10.1093/eurheartj/ehab607</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-6677-6229</orcidid><orcidid>https://orcid.org/0000-0002-7822-8852</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2021-12, Vol.42 (45), p.4694-4696
issn 0195-668X
1522-9645
language eng
recordid cdi_proquest_miscellaneous_2569374454
source Oxford Journals Online
subjects Humans
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors - adverse effects
Renal Insufficiency, Chronic - drug therapy
Ticagrelor - adverse effects
title Ticagrelor monotherapy in CKD: better safety at what price?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-08T16%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ticagrelor%20monotherapy%20in%20CKD:%20better%20safety%20at%20what%20price?&rft.jtitle=European%20heart%20journal&rft.au=Parker,%20William%20A%20E&rft.date=2021-12-01&rft.volume=42&rft.issue=45&rft.spage=4694&rft.epage=4696&rft.pages=4694-4696&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehab607&rft_dat=%3Cproquest_cross%3E2569374454%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c301t-e56697432d8c5f43a61cf7f23a63de3d11d51fc030f0fab331e5f4cb02cbf3143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2569374454&rft_id=info:pmid/34480540&rfr_iscdi=true